Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.
Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.
Former Teva CEO Jeremy Levin has taken the pilot's seat at a stealth biotech devoted to rare brain diseases and is piloting a course straight into the industry spotlight.
U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.
Nexvet Biopharma, which has been struggling to gain traction on Wall Street since its February IPO, said in a statement Wednesday that it is reassessing the study program for its lead compound, NV-01, after an initial review indicated that the current trial has a "low probability" of hitting the endpoint necessary for U.S. approval.
Biogen's latest treatment for multiple sclerosis helped repair damaged nerve tissue in a Phase II study, an incremental victory for a novel therapy that has a long way to go.
California's InPress Technologies completed the first human trial of its innovative device for postpartum hemorrhages, or excessive bleeding after childbirth, a milestone for the company as it eyes U.S. regulatory approval for the product.
AstraZeneca has signed on to partner with PatientsLikeMe to cull data from its network of some 250,000 patients that will help guide drug development at the pharma giant.
Researchers at UCLA have developed a new method for the delivery of large molecules into cells. The tool has shown in early tests that it can shuttle nanoparticles, enzymes, antibodies, bacteria and other materials into cells at up to 100,000 cells per minute.